Navidea biopharmaceuticals, inc. announces intent to sell cardinal milestone payment for $8 million; secures new $2.75 million equity line of credit

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the execution of a letter of intent to sale the cardinal milestone payment for $8 million and execution of a new $2.75 million equity line of credit, led by a longtime navidea investor, to provide substantial funding for the company's phase iib (nav3-32) and phase iii.
NAVB Ratings Summary
NAVB Quant Ranking